Literature DB >> 23947008

Epithelial-mesenchymal transition (EMT): principles and clinical impact in cancer therapy.

María Liliana Franco-Chuaire1, Sánchez-Corredor Magda Carolina, Lilian Chuaire-Noack.   

Abstract

The epithelial-mesenchymal transition (EMT) is a biological phenomenon responsible for the formation of different tissues and organs during normal metazoan development. Because of the connection of the EMT with the pathogenesis of certain diseases, such as cancer, the attention of the scientific community has been directed towards the search for and identification of effective therapeutic targets. These targets include signal transduction in cancerous stem cells and the use of microRNAs, which would inhibit EMT-associated phenotypic changes and tumoral progression. In an attempt to compile relevant and current information, this work addresses concepts that define the EMT and the advances in this field. The wealth of knowledge gained from areas such as the loss of cell polarity and intracellular adhesion complexes, the signaling pathways implicated, microRNA participation in this process, and stemness acquisition in embryonic and cancerous cells, all of which allow for the visualization of promising perspectives, particularly, methods for targeting advanced malignancies, are presented herein.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23947008

Source DB:  PubMed          Journal:  Invest Clin        ISSN: 0535-5133            Impact factor:   0.683


  25 in total

1.  Down-regulation of Gli-1 inhibits hepatocellular carcinoma cell migration and invasion.

Authors:  Jing-Song Chen; Hua-Shu Li; Jiong-Qiang Huang; Long-Juan Zhang; Xi-Lin Chen; Qian Wang; Jian Lei; Ju-Tao Feng; Qin Liu; Xiao-Hui Huang
Journal:  Mol Cell Biochem       Date:  2014-05-03       Impact factor: 3.396

2.  Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition.

Authors:  Ke-Zhu Hou; Zhi-Qiang Fu; Hua Gong
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

3.  FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.

Authors:  Fan-Di Meng; Ji-Chao Wei; Kai Qu; Zhi-Xin Wang; Qi-Fei Wu; Ming-Hui Tai; Hao-Chen Liu; Rui-Yao Zhang; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 4.  Drug Repurposing by Tumor Tissue Editing.

Authors:  Florian Lüke; Dennis Christoph Harrer; Pan Pantziarka; Tobias Pukrop; Lina Ghibelli; Christopher Gerner; Albrecht Reichle; Daniel Heudobler
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

5.  B-cell receptor-associated protein 31 promotes migration and invasion in ovarian cancer cells.

Authors:  Haiyan Liang; Jiqiao Dong; Ziyan Cheng; Qian Li; Dingqing Feng; Bin Ling
Journal:  Exp Ther Med       Date:  2021-06-09       Impact factor: 2.447

6.  HOXB9 promotes epithelial-to-mesenchymal transition via transforming growth factor-β1 pathway in hepatocellular carcinoma cells.

Authors:  Lin Sha; Lei Dong; Li Lv; Lizhi Bai; Xuening Ji
Journal:  Clin Exp Med       Date:  2014-08-01       Impact factor: 3.984

Review 7.  Long noncoding RNA HOTAIR involvement in cancer.

Authors:  Yansheng Wu; Li Zhang; Yang Wang; Hui Li; Xiubao Ren; Feng Wei; Wenwen Yu; Xudong Wang; Lun Zhang; Jinpu Yu; Xishan Hao
Journal:  Tumour Biol       Date:  2014-08-29

8.  MiR-26a inhibits prostate cancer progression by repression of Wnt5a.

Authors:  Shijia Zhao; Xiangdong Ye; Lei Xiao; Xuexiong Lian; Yupeng Feng; Feng Li; Li Li
Journal:  Tumour Biol       Date:  2014-06-28

9.  Litchi Seed Aqueous Extracts play a role in suppression of epithelial-mesenchymal transition, invasion and migration in breast cancer cells.

Authors:  Yanling Ma; Fei Yan; Wujie Wei; Jie Deng; Li Li; Li Liu; Jianhai Sun
Journal:  Cell Cycle       Date:  2020-01-10       Impact factor: 4.534

10.  Glabridin attenuates the migratory and invasive capacity of breast cancer cells by activating microRNA-200c.

Authors:  Xianqing Ye; Fei Jiang; Yuan Li; Juan Mu; Lu Si; Xingxing Wang; Shilong Ning; Zhong Li
Journal:  Cancer Sci       Date:  2014-05-21       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.